https://pubmed.ncbi.nlm.nih.gov/38117960
This editorial comment discusses advancements and challenges in robotic surgery in urology.
https://pubmed.ncbi.nlm.nih.gov/38117959
This scientific abstract is an editorial comment on a medical topic, published in the Urology Practice journal in 2024.
https://pubmed.ncbi.nlm.nih.gov/38117958
The Chicago 4.0 (CCv4.0) manometric diagnostic protocol shows substantial agreement and high concordance with the Chicago 3.0 (CCv3.0) protocol, with most manometric diagnoses having no reclassification of patients, and more restrictive criteria in CCv4.0 achieving better reclassification of patients with ineffective esophageal motility (IEM).
https://pubmed.ncbi.nlm.nih.gov/38117957
This study presents a case of generalized pustular psoriasis in a patient with an NFKB2 variant, highlighting the potential role of NFKB2 in the pathogenesis of pustular psoriasis.
https://pubmed.ncbi.nlm.nih.gov/38117956
A trans-cyclooctene compound was developed to scavenge bromine and improve selectivity in catalytic bromination reactions, also serving as a probe for mechanistic studies.
https://pubmed.ncbi.nlm.nih.gov/38117955
“Thoracic SMARCA4-deficient undifferentiated tumor is a highly aggressive, rare epithelial malignancy with poor prognosis and uncertain optimal treatment.”
https://pubmed.ncbi.nlm.nih.gov/38117954
The study found that zinc oxide and titanium dioxide nanoparticles inhibit biofilm formation and alter gene expression in Klebsiella pneumoniae, suggesting their potential in controlling multidrug-resistant infections in hospitals.
https://pubmed.ncbi.nlm.nih.gov/38117953
A new compound that inhibits both autophagy and REV-ERB shows promising results as a potential anticancer drug in a melanoma xenograft model.
https://pubmed.ncbi.nlm.nih.gov/38117952
Researchers have isolated and identified nine terpestacin-type sesterterpenoids from a phytopathogenic fungus, with maydistacin A showing anti-inflammatory effects in LPS-stimulated macrophages.
https://pubmed.ncbi.nlm.nih.gov/38117951
The abstract reports the discovery and optimization of a new DNA-PK inhibitor, compound 31t, which shows potent and selective inhibition of DNA-PK, favorable pharmacokinetic properties, and promising cancer cell growth inhibition in xenograft models.